Please Wait
Applying Filters...
menu
    • menu
    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    Aarti Pharmalabs is a partner of choice for pharmaceutical companies for APIs & Intermediates. Largest Indian producer of Caffeine.

    Virtual Booth

    Contact Supplier

    Axplora is your partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Stenoparib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans
    Allarity Therapeutics Opens Phase 2 Trial With US Veterans

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230960/0/en/Allarity-Therapeutics-announces-that-its-collaborative-Phase-2-trial-with-the-United-States-Veteran-s-Administration-Combining-Stenoparib-with-Temozolomide-in-Relapsed-Small-Cell-L.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Allarity Therapeutics Unveils Q3 Financials & Business Update
    Allarity Therapeutics Unveils Q3 Financials & Business Update

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188337/0/en/Allarity-Therapeutics-Provides-Third-Quarter-2025-Financial-Results-and-Provides-Business-Updates.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:
    Allarity Therapeutics Unveils Stenoparib/2x-121 Phase 2 Data:

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153846/0/en/Allarity-Therapeutics-Presents-New-Phase-2-Clinical-Data-for-Stenoparib-2X-121-Showing-Landmark-Median-Overall-Survival-Has-Now-Surpassed-25-Months.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025
    Allarity CEO to Present at Biomarkers & Precision Medicine 2025

    17 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/17/3151554/0/en/Allarity-Therapeutics-CEO-to-Present-at-Biomarkers-Precision-Medicine-2025.html

    GLOBENEWSWIRE
    17 Sep 2025
    Share Share
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer
    Allarity Gets FDA Fast Track for Stenoparib in Ovarian Cancer

    26 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/26/3139198/0/en/Allarity-Therapeutics-Granted-FDA-Fast-Track-Designation-for-Stenoparib-for-the-Treatment-of-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    26 Aug 2025
    Share Share
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2
    Allarity Therapeutics Doses Second Patient in Stenoparib Phase 2

    27 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/27/3106506/0/en/Allarity-Therapeutics-Announces-Dosing-of-Second-Patient-in-New-Phase-2-Trial-of-Stenoparib-in-Advanced-Ovarian-Cancer.html

    GLOBENEWSWIRE
    27 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.